Matasar, M. J. Et Al. 2021. Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab. BLOOD , vol.138, no.Supplement 1 , 3538.

Matasar, M. J., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., ... Sapunarova, K.(2021). Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab. BLOOD , vol.138, no.Supplement 1, 3538.

Matasar, Matthew Et Al. "Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab," BLOOD , vol.138, no.Supplement 1, 3538, 2021

Matasar, Matthew J. Et Al. "Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab." BLOOD , vol.138, no.Supplement 1, pp.3538, 2021

Matasar, M. J. Et Al. (2021) . "Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab." BLOOD , vol.138, no.Supplement 1, p.3538.

@article{article, author={Matthew J. Matasar Et Al. }, title={Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab}, journal={BLOOD}, year=2021, pages={3538} }